Table 3.
Fabry treated patients with and without colocalization
Variables | Fabry treated with colocalization | Fabry treated without colocalization | P |
---|---|---|---|
(n = 11) (33%) | (n = 22) (67%) | ||
Age (years) | 36 (20–88) | 38.5 (18–76) | NS |
Gender, male [n(%)] | 3 (27) | 9 (41) | – |
eGFR (CKD-EPI) (mL/min/1.73 m2) | 101.6 (40.7–119) | 104.2 (18.2–156) | NS |
UPCR (g/g) | 0.07 (0.04–0.34) | 0.10 (0.05–2.45) | 0.04 |
Podocyturia/creatininuria (cells/g) | 0.35 (0.12–0.43) | 0.10 (0–0.43) | 0.0003 |
Lyso-Gb3 (nmol/L) | 3.10 (2.9–6.4) | 7.25 (3.2–12.0) | NS |
Time on therapy (months) | 96 (15–168) | 48 (13–180) | NS |
Data are presented as median (range) unless otherwise indicated.
NS, non-significant.